IVERIC bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-16: Form 8-K; Period of report 2016-12-15; Description 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events; Details 2.05.
- 2016-12-12: Form 8-K; Period of report 2016-12-12; Description 8.01 Other Events; Details 8.01.
- 2016-11-08: Form 8-K; Period of report 2016-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-11-04: Form 8-K; Period of report 2016-10-31; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-16 | 8-K | 2016-12-15 | 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.05 Ophthotech Corporation (the “Company” or “Ophthotech”) has determined to implement a reduction in personnel to focus on an updated business plan involving an expected workforce of approximately 20 to 30 employees. 8.01 The information disclosed under Item 2.05 of this Form 8-K is incorporated by reference in this Item 8.01. | a16-23283_18k.htm |
| 2016-12-12 | 8-K | 2016-12-12 | 8.01 Other Events | 8.01 On December 12, 2016, Ophthotech Corporation issued a press release announcing the results from two pivotal Phase 3 clinical trials of Fovista® administered in combination with Lucentis® in wet age related macular degeneration. | a16-22988_18k.htm |
| 2016-11-08 | 8-K | 2016-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2016, Ophthotech Corporation announced its financial results for the quarter ended September 30, 2016. | a16-21244_18k.htm |
| 2016-11-04 | 8-K | 2016-10-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a16-21108_18k.htm |
| 2016-08-03 | 8-K | 2016-07-29 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On August 3, 2016, Ophthotech Corporation announced its financial and operating results for the quarter ended June 30, 2016 and provided an update on its business and product development programs. 5.02 On July 29, 2016, the Board of Directors (the “Board”) of Ophthotech Corporation (the “Company”) elected Ian Smith as a director of the Company, effective as of August 2, 2016. | a16-16013_18k.htm |
| 2016-06-08 | 8-K | 2016-06-02 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 Entry into a Material Definitive Agreement. 5.02 Effective June 6, 2016, the Compensation Committee (the “Committee”) of the Board approved grants of restricted stock units (“RSUs”) with performance-based vesting criteria related to regulatory milestones for Fovista® to Ophthotech employees, including David R. Guyer, M.D., Chief Executive Officer; Samir C. Patel, M.D., President; Glenn P. Sblendorio, Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer; Barbara Wood, Senior Vice President and General Counsel; and Henric J. Bjarke, Senior Vice President, Chief Commercial Officer. 5.07 Ophthotech held its Annual Meeting of Stockholders on June 2, 2016. | a16-13056_18k.htm |
| 2016-05-09 | 8-K | 2016-05-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 6, 2016, Nicholas Galakatos, Ph.D. resigned from the Board of Directors of Ophthotech Corporation. | a16-10861_18k.htm |
| 2016-05-04 | 8-K | 2016-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On My 4, 2016, Ophthotech Corporation announced its financial results for the quarter ended March 31, 2016. | a16-10512_18k.htm |
| 2016-04-01 | 8-K | 2016-03-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Pursuant to previously disclosed arrangements, Glenn P. Sblendorio has assumed the position of Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer of Ophthotech Corporation (the “Company”) effective as of April 1, 2016, following the retirement of Michael G. Atieh as the Company’s Executive Vice President, Chief Financial and Business Officer and Treasurer effective as of March 31, 2016. | a16-7749_18k.htm |
| 2016-02-24 | 8-K | 2016-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2016, Ophthotech Corporation announced its financial results for the quarter and year ended December 31, 2015. | a16-5125_18k.htm |
| 2016-01-06 | 8-K | 2016-01-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 4, 2016, the Board of Directors (the “Board”) of Ophthotech Corporation (the “Company”) elected David E. Redlick as a director of the Company. | a16-1186_38k.htm |
| 2016-01-05 | 8-K | 2016-01-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 4, 2016, in connection with the notification by Michael G. Atieh of his decision to retire as Executive Vice President, Chief Financial and Business Officer, and Treasurer (collectively, “CFO”) of Ophthotech Corporation (the “Company”), the Company entered into a separation agreement and general release (the “Separation Agreement”) with Mr. Atieh. | a16-1186_18k.htm |